Liver Cirrhosis
Conditions
Brief summary
Individuals with metabolic syndrome (MetS), particularly those with type 2 diabetes (T2D), and/or metabolic dysfunction-associated steatohepatitis or MASH face an elevated risk of major cardiovascular events (MACE). We showed decrease plams level of PPi in patients with liver cirrhosis. We hypothezised that liver transplant should block AC and restore PPi plasma level.
Interventions
OTHERa blood test and urine sample collection.
The study is offered to all patients who meet the inclusion criteria during their pre-transplant assessment by the principal investigator (during an existing visit). Patients eligible for HT are contacted by a clinical research coordinator, and if they agree, an inclusion visit is arranged.
Sponsors
Centre Hospitalier Universitaire de Nice
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* everyone requiring liver transplantation for the treatment of a chronic liver disease
Exclusion criteria
* MELD score \>25, viral replication
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| hepatic transplantation reduces arterial calcification | On the 7th day after surgery | compare the percent of patients with AC progression before and after liver tranplantation |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| identify arterial calcification related factors | On the 7th day after surgery | separation of patients according to AC progression (yes or no) and machine learning analysis with all relevant factors |
| increase of PPi plasma level after liver transplantation | at inclusion and at 3 months | comparison of mean plasma levels before and after |
Countries
France
Contacts
Primary ContactGuillaume FAVRE, PhD
Backup ContactGullaume Marrane
Outcome results
None listed